von Arx, L. B., Rachman, J. ., Webb, J. ., Casey, C. ., Patel, A. ., Diomatari, C. ., … Idris, I. . (2023). Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care. Diabetes Obes Metab. http://doi.org/10.1111/dom.14985
Type 2 diabetes
group, D. working. (2022). Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwac232
Bidulka, P. ., Mathur, R. ., Lugo-Palacios, D. G., O’Neill, S. ., Basu, A. ., Silverwood, R. J., … Grieve, R. . (2022). Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14874
Brunetti, V. C., St-Jean, A. ., Dell’Aniello, S. ., Fisher, A. ., H. Y. Yu, O. ., Bugden, S. C., … Filion, K. B. (2022). Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. BMC Endocr Disord, 22, 241. http://doi.org/10.1186/s12902-022-01140-1
Sarodnik, C. ., Rasmussen, N. H., Bours, S. P. G., Schaper, N. C., Vestergaard, P. ., Souverein, P. C., … van den Bergh, J. P. W. (2022). The incidence of fractures at various sites in newly treated patients with type 2 diabetes mellitus. Bone Rep, 17, 101614. http://doi.org/10.1016/j.bonr.2022.101614
Xu, Z. ., Arnold, M. ., Sun, L. ., Stevens, D. ., Chung, R. ., Ip, S. ., … Wood, A. M. (2022). Incremental value of risk factor variability for cardiovascular risk prediction in individuals with type 2 diabetes: results from UK primary care electronic health records. Int J Epidemiol. http://doi.org/10.1093/ije/dyac140
Idris, I. ., Zhang, R. ., Mamza, J. B., Ford, M. ., Morris, T. ., Banerjee, A. ., & Khunti, K. . (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
Alkabbani, W. ., Zongo, A. ., Minhas-Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. M. (2021). Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study. Can J Diabetes. http://doi.org/10.1016/j.jcjd.2021.12.005
Mueller, A. M., Meier, C. R., Jick, S. S., & Schneider, C. . (2022). Characterization of the deterioration of diabetes control in patients with a subsequent diagnosis of pancreatic cancer: A descriptive study. Pancreatology. http://doi.org/10.1016/j.pan.2022.03.012
Pradhan, R. ., Yu, O. ., Platt, R. W., & Azoulay, L. . (2022). Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom. Diabetes Res Clin Pract, 185, 109229. http://doi.org/10.1016/j.diabres.2022.109229